A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia

Abstract Background Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL. Methods We conducted a single‐arm multi‐center Pha...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Aref Al‐Kali, Ibrahim Aldoss, Pamela J. Atherton, Carrie A. Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Sarah A. Buhrow, Jianping Kong, Joel M. Reid, Alex A. Adjei, Scott H. Kaufmann
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-12-01
coleção:	Cancer Medicine
Assuntos:	acute lymphoblastic leukemia ALL mTOR inhibitor sapanisertib
Acesso em linha:	https://doi.org/10.1002/cam4.6701
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!